Drug Trial Radar · NCT04412577
A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies
Last checked: Nov 19, 2026Latest source record: Apr 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
57
Planned (sponsor's estimate)
Start
Oct 12, 2020
Primary completion
Dec 2021
Study completion Jun 2022
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the maximum tolerated dose (MTD), occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3473 tablets in Chinese adult patients with Relapsed or refractory hematological malignancies.
Conditions
- Relapsed/Refractory Hematological Malignancies
Interventions
TQB3473Drug
TQB3473 tablets administered orally once. Then TQB3473 tablets administered orally, once daily in 28-day cycle after 3 days of first administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD)Time frame: up to 31 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.